FGFR2 and cholangiocarcinoma: These data led to the approval of Pemigatinib as a second-line treatment for patients with metastatic/advanced CCA harbouring a FGFR2 fusion or another FGFR2-associated rearrangement, first by the FDA and more recently by the EMA.